Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Страница 1 от 61 полученные результаты
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND
Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke,
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND
Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect (PBA) were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). The PRISM II study provides additional DM/Q experience with PBA secondary to
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Adverse hemodynamic effects of intravenous disopyramide compared with quinidine in conscious dogs.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Disopyramide resembles quinidine electrophysiologically, but its effect on left ventricular function has not been clarified. Twelve awake dogs were instrumented for measurement of cardiac output, left ventricular pressure and its maximal first derivative (dP/dt max), and left atrial and aortic
Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Cryptotanshinone (CTS), a major constituent from the roots of Salvia miltiorrhiza (Danshen), is widely used in the treatment of coronary heart disease, stroke and less commonly Alzheimer's disease. Our recent study indicates that CTS is a substrate for P-glycoprotein (PgP/MDR1/ABCB1). This study has
Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
OBJECTIVE
To compare the relative risks and benefits of several clinical strategies for managing patients with chronic atrial fibrillation.
METHODS
Five recent randomized controlled trials of warfarin in atrial fibrillation, 6 randomized controlled trials of quinidine, and 13 longitudinal studies of
[Quinidine-induced syncope simulating transient cerebral ischemic attack].
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
A case of quinidine-induced syncope with prevailing neurological symptoms is reported in which the transient right-sided hemiparesis and fluctuating soporific state was induced by recurrent torsades de pointes ventricular tachycardias. In connection with this case, attention is paid to the
Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The pharmacokinetics and haemodynamics (phono- and impedance cardiography) of single oral doses of 200 mg ibopamine (SK&F 100168), 400 mg quinidine sulphate, and their combination, have been assessed in 6 healthy male volunteers. No significant differences in the mean pharmacokinetic parameters of
Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Pseudobulbar affect (PBA) is a common manifestation of brain pathology associated with many neurological diseases, including amyotrophic lateral sclerosis, Alzheimer's disease, stroke, multiple sclerosis, Parkinson's disease, and traumatic brain injury. PBA is defined by involuntary and
The hemodynamic effects of sotalol and quinidine: analysis by use of rest and exercise gated radionuclide angiography.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
This placebo-controlled, double-blind trial compared the hemodynamic effects of sotalol and quinidine with the use of rest and exercise gated radionuclide angiography. Patients had frequent ventricular premature depolarizations (greater than or equal to 30 VPDs/hour) and depressed cardiac function
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND
Dextromethorphan 20 mg / quinidine 10 mg (DM/Q) was approved to treat pseudobulbar affect (PBA) based on phase 3 trials conducted in participants with amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness, safety, and tolerability for PBA following
[The effect of quinidine monotherapy and combined therapy with digoxin on the central hemodynamics in patients with heart rhythm disorders].
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The study was undertaken to examine 84 patients mainly with coronary heart disease and various cardiac arrhythmias. Quinidine monotherapy was found to normalize heart rate depending on its baseline values: it reduced heart rate in tachycardias and increased it in bradycardia. In patients with severe
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Anticoagulation for stroke prevention in atrial fibrillation (AF) is effective. Pivotal trials RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE-AF TIMI 48 tested novel agents against warfarin (W). In RE-LY, an open-label trial, dabigatran 150 mg BID (D150) was superior (35%) and 110 mg BID (D110) was
Intracranial hemorrhage associated with quinidine induced thrombocytopenia.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Quinidine is commonly used in the treatment of atrial and ventricular arrhythmias. Such patients are at increased risk for embolic strokes and may require concurrent anticoagulation therapy. We report here the occurrence of intracranial hemorrhage as a complication of thrombocytopenia in two
Hemodynamic effects of intravenously administered quinidine on the transplanted human heart.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The acute hemodynamic effects of intravenously administered quinidine were studied in five heart transplant recipients with an anatomically denervated heart. Quinidine, 10 mg/kg body weight, was infused over a 20 minute period, and mild wall left ventricular dynamics were measured with a new
Самая полная база данных о лекарственных травах, подтвержденная наукой
- Работает на 55 языках
- Травяные лекарства, подтвержденные наукой
- Распознавание трав по изображению
- Интерактивная карта GPS - отметьте травы на месте (скоро)
- Прочтите научные публикации, связанные с вашим поиском
- Ищите лекарственные травы по их действию
- Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов
Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.
